[{"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-001", "question": "A 16-year-old male presents with recurrent stroke-like episodes, mitochondrial myopathy, and lactic acidosis. Muscle biopsy reveals 38% heteroplasmy for the m.3243A>G mutation. Based on current mitochondrial disease criteria, what is the significance of this heteroplasmy level?", "options": ["Insufficient for MELAS diagnosis; >60% required in muscle", "Diagnostic of MELAS; clinical correlation unnecessary", "Above the threshold for clinical expression; supports diagnosis with compatible phenotype", "Only significant if confirmed in blood at >20%", "Requires repeat biopsy; sampling error likely"], "answer": "C", "answer_index": 2, "explanation": "In MELAS, >40% heteroplasmy in muscle correlates with clinical manifestation, but levels of 30-40% with typical phenotype are considered diagnostic. Blood heteroplasmy is less sensitive and declines with age. The threshold concept is critical for interpreting borderline results.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to consider the significance of 38% heteroplasmy for the m.3243A>G mutation in muscle tissue for a patient with symptoms consistent with MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes).\n\nThe m.3243A>G mutation is the most common mutation associated with MELAS syndrome. Heteroplasmy refers to the percentage of mitochondrial DNA that carries the mutation.\n\nFor the m.3243A>G mutation:\n- There is no absolute threshold of heteroplasmy required for diagnosis\n- Muscle tissue typically shows higher heteroplasmy levels than blood\n- Clinical expression generally occurs when heteroplasmy exceeds 10-30% in affected tissues\n- The correlation between heteroplasmy level and disease severity is not absolute\n- Diagnosis requires both genetic findings and compatible clinical features\n\nA 38% heteroplasmy level in muscle is above the typical threshold for clinical expression. This finding, combined with the patient's clinical presentation (stroke-like episodes, mitochondrial myopathy, and lactic acidosis), supports the diagnosis of MELAS.\n\nThe diagnosis doesn't require >60% heteroplasmy, doesn't require blood confirmation at a specific level, and doesn't require repeat biopsy. However, the genetic finding alone is not diagnostic without clinical correlation.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-002", "question": "A 19-year-old asymptomatic athlete has a QTc of 315ms on pre-participation screening. Family history reveals sudden cardiac death in a paternal uncle. Genetic testing identifies a gain-of-function KCNH2 mutation (c.1764G>C). According to 2022 ESC guidelines for SQTS, what is the recommended management?", "options": ["No therapy; restriction from competitive sports", "Implantable cardioverter-defibrillator regardless of symptoms", "Quinidine 600mg daily to maintain QTc >360ms", "Flecainide 100mg twice daily for rhythm stabilization", "Annual Holter monitoring without pharmacotherapy"], "answer": "C", "answer_index": 2, "explanation": "For asymptomatic SQTS patients with pathogenic KCNH2 mutations, quinidine is recommended to prolong QT interval and reduce arrhythmia risk. ICD is reserved for symptomatic patients or those with aborted SCD. Flecainide is contraindicated in SQTS.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to analyze the case of a young athlete with Short QT Syndrome (SQTS) based on the 2022 ESC guidelines.\n\nThe key elements in this case are:\n- 19-year-old asymptomatic athlete\n- Very short QTc (315ms)\n- Family history of sudden cardiac death in a paternal uncle\n- Confirmed gain-of-function KCNH2 mutation (c.1764G>C)\n\nSQTS is a rare but potentially lethal channelopathy characterized by abnormally short QT intervals. The KCNH2 gain-of-function mutation is associated with SQTS type 1, one of the most common and well-characterized forms.\n\nAccording to the 2022 ESC guidelines for management of patients with ventricular arrhythmias and prevention of sudden cardiac death:\n\n1. ICD implantation is recommended for SQTS patients who:\n   - Have survived cardiac arrest\n   - Have documented spontaneous sustained VT\n   - Have a family history of SCD and evidence of shortened QT interval\n\n2. Quinidine should be considered in SQTS patients:\n   - Who qualify for an ICD but have contraindications or refuse the device\n   - As an adjunctive therapy to ICD to suppress arrhythmias\n   - To increase the QT interval toward normal values\n\nGiven this patient's very short QTc, family history of SCD, and confirmed pathogenic mutation, despite being asymptomatic, an ICD would be the recommended intervention according to the 2022 ESC guidelines.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-003", "question": "A 62-year-old woman with Graves disease presents in thyroid storm (Burch-Wartofsky score 65) with pulmonary edema and cardiogenic shock (LVEF 15%, CI 1.8 L/min/m²). She cannot tolerate beta-blockers due to severe decompensation. Which vasoactive agent is most appropriate initial therapy?", "options": ["Norepinephrine for vasopressor support", "Dobutamine for inotropic effect", "Milrinone 0.5 mcg/kg/min for inodilation", "Levosimendan 0.1 mcg/kg/min calcium sensitizer", "Dopamine 10 mcg/kg/min for combined effect"], "answer": "C", "answer_index": 2, "explanation": "In thyroid storm with cardiogenic shock, beta-blockers are contraindicated. Milrinone provides inotropy via phosphodiesterase inhibition independent of beta-adrenergic receptors and offers vasodilation to reduce afterload. Levosimendan is less preferred due to limited data and potential arrhythmogenicity.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to consider the patient's condition and the most appropriate vasoactive agent.\n\nThe patient has:\n- Thyroid storm (severe hyperthyroidism)\n- Pulmonary edema\n- Cardiogenic shock with low cardiac index (CI 1.8 L/min/m²)\n- Severely reduced left ventricular ejection fraction (LVEF 15%)\n- Cannot tolerate beta-blockers due to severe decompensation\n\nIn thyroid storm with cardiogenic shock, the patient needs inotropic support to improve cardiac output. However, the choice of agent is complicated by the inability to use beta-blockers.\n\nAnalyzing each option:\nA. Norepinephrine: Primarily a vasopressor that increases SVR but may worsen cardiac workload\nB. Dobutamine: Beta-agonist that would worsen tachycardia in thyroid storm\nC. Milrinone: Phosphodiesterase inhibitor that provides inotropic support without direct beta-stimulation\nD. Levosimendan: Calcium sensitizer that improves contractility without increasing oxygen demand\nE. Dopamine: Has both alpha and beta effects that could worsen tachycardia\n\nFor this patient, an agent that can improve cardiac output without exacerbating the hyperdynamic state of thyroid storm is needed. Milrinone would be most appropriate as it provides inotropic support through a mechanism independent of beta-adrenergic stimulation.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-004", "question": "A 6-year-old boy presents with recurrent lacunar strokes, livedo racemosa, and systemic vasculitis. ADA2 enzyme activity is <5% of normal. Genetic testing confirms biallelic loss-of-function ADA2 mutations. What is the first-line therapy for preventing further cerebrovascular events?", "options": ["High-dose prednisone with cyclophosphamide induction", "Rituximab 750mg/m² every 4 weeks", "Etanercept 0.8mg/kg weekly subcutaneously", "Anakinra 2mg/kg daily subcutaneously", "Aspirin 5mg/kg daily antiplatelet therapy"], "answer": "C", "answer_index": 2, "explanation": "DADA2 is a monogenic interferonopathy where TNF-α drives vasculitic manifestations. TNF inhibition with etanercept prevents stroke recurrence and treats systemic vasculitis, while traditional immunosuppressants are ineffective. IL-1 blockade is second-line.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to identify the condition and its first-line treatment.\n\nThe patient has:\n- Recurrent lacunar strokes\n- Livedo racemosa\n- Systemic vasculitis\n- Severely reduced ADA2 enzyme activity (<5%)\n- Confirmed biallelic loss-of-function ADA2 mutations\n\nThis is a classic presentation of Deficiency of Adenosine Deaminase 2 (DADA2), a rare autoinflammatory disorder.\n\nFor DADA2, anti-TNF therapy is considered the first-line treatment for preventing cerebrovascular events. This is because:\n- TNF inhibitors have shown significant efficacy in preventing strokes in DADA2\n- They address the underlying inflammatory process\n- They have demonstrated better outcomes than steroids or other immunosuppressants\n\nAmong the options, etanercept (a TNF inhibitor) at 0.8mg/kg weekly subcutaneously would be the first-line therapy for this condition.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-005", "question": "A 30-year-old G2P1 at 32 weeks gestation presents with fetal hydrops and mirror syndrome. Which pathophysiologic mechanism best explains her severe preeclampsia-like features?", "options": ["Massive fetomaternal hemorrhage causing maternal anemia", "Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1)", "Maternal antibody production against fetal Rh antigens", "Amniotic fluid embolism triggering systemic inflammation", "Mirror syndrome is a misdiagnosis; this is atypical HELLP"], "answer": "B", "answer_index": 1, "explanation": "Mirror syndrome involves placental edema that mechanically compromises uteroplacental perfusion and releases anti-angiogenic factors like sFlt-1, creating a preeclampsia phenotype. Resolution occurs within 48 hours of delivery or fetal therapy that reduces hydrops.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to understand the pathophysiology of mirror syndrome and its relationship to preeclampsia-like features.\n\nMirror syndrome (also called Ballantyne syndrome) is a rare condition characterized by maternal edema that \"mirrors\" fetal hydrops. It presents with preeclampsia-like features including hypertension, proteinuria, and edema.\n\nLet's analyze each option:\n\nA. Massive fetomaternal hemorrhage causing maternal anemia - While fetomaternal hemorrhage can cause fetal hydrops, it doesn't explain the preeclampsia-like features in mirror syndrome.\n\nB. Placental edema releasing soluble fms-like tyrosine kinase-1 (sFlt-1) - This is the most likely mechanism. In mirror syndrome, placental edema leads to increased production of anti-angiogenic factors like sFlt-1, similar to preeclampsia. sFlt-1 antagonizes vascular endothelial growth factor (VEGF), leading to endothelial dysfunction and the preeclampsia-like features.\n\nC. Maternal antibody production against fetal Rh antigens - While this can cause fetal hydrops, it doesn't directly explain the maternal preeclampsia-like features.\n\nD. Amniotic fluid embolism triggering systemic inflammation - This is an acute, life-threatening condition unrelated to mirror syndrome.\n\nE. Mirror syndrome is a misdiagnosis; this is atypical HELLP - Mirror syndrome is a distinct entity, not a misdiagnosis of HELLP syndrome.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-006", "question": "A 50-year-old with eosinophilic granulomatosis with polyangiitis undergoes cardiac MRI for suspected myocarditis. Late gadolinium enhancement shows predominant subendocardial involvement with sparing of the epicardium. What is the prognostic implication?", "options": ["Indicates active eosinophilic myocarditis responsive to steroids", "Suggests concomitant coronary artery disease requiring angiography", "Represents fibrotic replacement predicting poor response to immunosuppression", "Typical pattern with no impact on treatment decisions", "Requires endomyocardial biopsy for definitive diagnosis"], "answer": "C", "answer_index": 2, "explanation": "In EGPA, subendocardial LGE pattern indicates chronic fibrotic replacement rather than active inflammation, predicting poor response to immunosuppressive therapy and worse cardiac outcomes. Epicardial LGE correlates with active myocarditis and treatment responsiveness.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to analyze the cardiac MRI findings in a patient with eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss syndrome).\n\nThe key finding is late gadolinium enhancement (LGE) with predominant subendocardial involvement and epicardial sparing. This pattern is significant in EGPA cardiac involvement.\n\nIn EGPA with cardiac involvement, the disease typically progresses through stages:\n1. Acute eosinophilic infiltration (active myocarditis)\n2. Thrombotic stage\n3. Fibrotic stage with scarring\n\nThe subendocardial pattern of LGE in this case is consistent with fibrotic replacement of the myocardium, which represents a late/chronic stage of cardiac involvement. This fibrotic tissue replaces previously damaged myocardium and is generally irreversible.\n\nWhen fibrotic replacement has occurred, the response to immunosuppressive therapy is typically poor, as the damage is permanent. This contrasts with active eosinophilic myocarditis, which would show different MRI patterns and might respond better to steroids and immunosuppression.\n\nThe answer is (C)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-007", "question": "An 11-month-old infant presents with a large CNS tumor. Histopathology shows rhabdoid cells with loss of SMARCB1 immunostaining. Molecular profiling reveals a TYR-methylation class. What is the most critical prognostic factor in this subtype?", "options": ["Presence of SMARCB1 deletion alone", "Age <3 years at diagnosis", "MYC oncogene amplification status", "DNA methylation subclassification", "Extent of surgical resection"], "answer": "D", "answer_index": 3, "explanation": "In ATRT, the methylation class (TYR, SHH, MYC) is the dominant prognostic factor, with TYR class having 90% 5-year survival compared to <30% for MYC. SMARCB1 loss is universal, and age is secondary to molecular subclassification in risk stratification.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "E", "model_outputs": "To answer this question, I need to analyze the case of an infant with a CNS tumor showing rhabdoid histology and SMARCB1 loss.\n\nThe patient has:\n- 11-month-old infant\n- CNS tumor with rhabdoid cells\n- Loss of SMARCB1 immunostaining\n- TYR-methylation class\n\nThis description is consistent with an atypical teratoid/rhabdoid tumor (ATRT), which is characterized by SMARCB1 loss. ATRTs are now classified into molecular subgroups based on DNA methylation profiling, with TYR (ATRT-TYR) being one of the recognized subgroups.\n\nFor ATRT-TYR subtype specifically:\n- DNA methylation subclassification (option D) is indeed important for diagnosis but not the most critical prognostic factor\n- SMARCB1 deletion (option A) is a diagnostic feature but not the key prognostic determinant\n- Age (option B) is generally important in pediatric brain tumors, but not the most critical factor specific to this subtype\n- MYC amplification (option C) is more relevant in other CNS tumor types\n- Extent of surgical resection (option E) has been consistently shown to be the most significant prognostic factor in ATRT cases, including the TYR subtype\n\nThe extent of surgical resection has been demonstrated in multiple studies to be the single most important factor affecting survival outcomes in ATRT patients, regardless of molecular subtype.\n\nThe answer is (E)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-008", "question": "A 76-year-old man with wild-type transthyretin amyloidosis (ATTRwt) has LV wall thickness 16mm and LVEF 45%. Which speckle-tracking echocardiographic finding best distinguishes this from hypertensive heart disease?", "options": ["Global longitudinal strain -8%", "Relative apical sparing ratio >1.5", "Basal sparing pattern", "Circumferential strain >-15%", "Longitudinal strain <10% with basal predominance"], "answer": "B", "answer_index": 1, "explanation": "Relative apical sparing ratio (average apical strain / average basal strain) >1.5 is 93% specific for cardiac amyloidosis, reflecting base-to-apex gradient of amyloid deposition. This pattern is not seen in hypertensive heart disease where strain reduction is homogeneous.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To distinguish wild-type transthyretin amyloidosis (ATTRwt) from hypertensive heart disease using speckle-tracking echocardiography, I need to identify the most specific pattern for cardiac amyloidosis.\n\nCardiac amyloidosis has a characteristic pattern on strain imaging:\n\nA. Global longitudinal strain -8%: While reduced GLS is common in amyloidosis, this finding alone is nonspecific and can occur in many cardiomyopathies.\n\nB. Relative apical sparing ratio >1.5: This is the classic \"cherry on top\" or \"bull's eye\" pattern seen in cardiac amyloidosis, where the apex maintains better strain compared to the mid and basal segments. This pattern is highly specific for cardiac amyloidosis and helps differentiate it from other causes of LV hypertrophy like hypertensive heart disease.\n\nC. Basal sparing pattern: This is the opposite of what's typically seen in amyloidosis, which characteristically shows basal involvement with relative apical sparing.\n\nD. Circumferential strain >-15%: Reduced circumferential strain can occur in amyloidosis but is not a distinguishing feature.\n\nE. Longitudinal strain <10% with basal predominance: While amyloidosis does affect basal segments, the distinguishing feature is the relative preservation of apical strain compared to basal segments.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-009", "question": "A 45-year-old woman with severe verapamil overdose (ingestion 4 hours ago) presents with hypotension (SBP 70mmHg) and hyperglycemia (420mg/dL). You initiate high-dose insulin euglycemia therapy (HIET). What is the target serum glucose range during the first 24 hours?", "options": ["80-110 mg/dL (tight glycemic control)", "110-180 mg/dL (moderate control)", "180-250 mg/dL (permissive hyperglycemia)", "250-350 mg/dL (severe hyperglycemia acceptable)", "No specific target; follow institutional protocol"], "answer": "B", "answer_index": 1, "explanation": "HIET requires maintaining glucose 110-180 mg/dL to prevent hypoglycemia during high-dose insulin infusion (0.5-1 unit/kg/hr) while allowing insulin's inotropic effects. Tighter targets risk hypoglycemia; higher targets may impair insulin's metabolic benefits.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "For high-dose insulin euglycemia therapy (HIET) in calcium channel blocker overdose like verapamil, the goal is not to achieve tight glycemic control but rather to maintain adequate glucose levels while allowing the high-dose insulin to exert its inotropic effects. \n\nIn HIET, insulin is given at much higher doses than for typical diabetic management (often 1 unit/kg bolus followed by 1-10 units/kg/hr infusion). At these doses, the primary purpose is to improve cardiac contractility and vascular tone, not to control hyperglycemia.\n\nDuring HIET, moderate glycemic control is preferred to avoid hypoglycemia while still preventing extreme hyperglycemia. The target range of 110-180 mg/dL represents this balanced approach, allowing for the metabolic effects of high-dose insulin while maintaining reasonable glucose levels.\n\nTighter control (80-110 mg/dL) would increase hypoglycemia risk, while permitting higher levels (>180 mg/dL) without a specific therapeutic purpose would not be standard practice.\n\nThe answer is (B)"}, {"quiz_id": "20251205T080918850Z_kimi-k2-thinking_seed126", "question_id": "20251205T080918850Z_kimi-k2-thinking_seed126-010", "question": "A 35-year-old man develops DRESS syndrome 3 weeks after starting phenytoin. He has fever, eosinophilia, atypical lymphocytosis, and transaminitis (AST 450 U/L). HHV-6 PCR becomes positive at day 16 of illness. What is the clinical significance of this virologic finding?", "options": ["Confirms phenytoin as the causative drug", "Indicates need for ganciclovir antiviral therapy", "Predicts higher risk of disease flare and organ damage", "Represents asymptomatic viral reactivation without prognostic value", "Suggests alternative diagnosis of acute HHV-6 infection"], "answer": "C", "answer_index": 2, "explanation": "HHV-6 reactivation at weeks 2-3 in DRESS is pathogenically linked to disease severity, predicting higher risk of relapse, end-organ damage, and prolonged course. It indicates need for more aggressive immunosuppression, not antiviral therapy, as the virus is a marker of immune dysregulation.", "generator_model": "kimi-k2-thinking", "seed": 126, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to consider the relationship between DRESS syndrome and HHV-6 reactivation.\n\nDRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) is a severe drug-induced hypersensitivity reaction. The patient has classic features: fever, eosinophilia, atypical lymphocytosis, and liver involvement after starting a high-risk medication (phenytoin).\n\nThe detection of HHV-6 (Human Herpesvirus 6) by PCR during DRESS syndrome is a well-documented phenomenon. Research has shown that viral reactivation, particularly HHV-6, frequently occurs during DRESS syndrome. This reactivation is not the primary cause of DRESS but rather a consequence of the immune dysregulation triggered by the drug hypersensitivity reaction.\n\nThe positive HHV-6 PCR:\n- Doesn't confirm phenytoin as the cause (the clinical presentation does that)\n- Doesn't require specific antiviral therapy as standard practice\n- Doesn't suggest an alternative diagnosis (the clinical picture is classic for DRESS)\n- Has been associated in some studies with more severe disease course and potential flares\n- Represents viral reactivation that commonly occurs during DRESS syndrome\n\nBased on current understanding of DRESS syndrome, HHV-6 reactivation has been associated with more severe disease and risk of flares.\n\nThe answer is (C)"}]